Phase I safety study of interferon alfacon-1 in health volunteers - Pharmacodynamic response

Japanese Pharmacology and Therapeutics

Volumn 27, Issue 3, 1999, Pages 217-226

  Azuma, Junichi ^a  

^a Osaka Pharmacology Research Clinic   (Japan)

Author keywords

2 microglobulin; 2',5' oligoadenylate synthetase; Interferon alfacon 1; Phase I study; Safety

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BETA 2 MICROGLOBULIN; CONSENSUS INTERFERON; INTERFERON; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032930829     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Alton K et al : Production, characterization and biological effects of recombinant DNA derived human IFN- and IFN-analogs. De Maeyer E, Schellekens H ed, The Biology of the Interferon System 1983. p 119-128, Elsevier Science Publishers, Amsterdam, 1983
2. Tong MJ et al : Treatment of chronic hepatitis C with consensus interferon : A multicenter, randomized, controlled trial. Hepatology 26: 747-754, 1997
3. Heathcote EJ et al : Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 27: 1136-1143, 1998
4. Renault PF, Hoofnagle JH : Side effects of alpha interferon. Semin Liver Dis 9: 273-277, 1989
5. Aulitzky WE et al : Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2. Ann Hematol 62: 25-31, 1991
6. Aulitzky W et al : Interferon-alpha in the treatment of hematologic neoplasms. Wien Med Wochenschr 136: 172-181, 1986
7. Sugawara T : 2′,5′-oligoadenylate synthetase activity in peripheral blood mononuclear cells obtained from patients with chronic hepatitis B during interferon- therapy. Hokkaido Igaku Zasshi 65: 439-454, 1990
8. Moritz T et al : Induction of 2′-5′ oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia. Mol Biother 4: 97-102, 1992
9. Karino Y : Mechanisms of the effect of interferon (IFN) therapy in patients with type B and C chronic hepatitis. Hokkaido Igaku Zasshi 68: 297-309, 1993
10. Solinas A et al : Changes of serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. Liver 13: 253-258, 1993
11. Aulitzky WE et al : Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia. Ann Hematol 67: 205-211, 1993
12. Saito T et al : A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 89: 681-686, 1994
13. Merritt JA et al : Modulation of 2′,5′ oligoadenylate synthetase in patients treated with alpha-interferon : effects of dose, schedule, and route of administration. J Interferon Res 6: 189-198, 1986
14. Witt PL et al : Pharmacodynamics of biological response in vivo after single and multiple dose of interferon-beta. J Immunother 13: 191-200, 1993